Efficacy Study of Zenapax in Combination With CellCept, Cyclosporine and Corticosteroids in Heart Transplant

This study has been completed.
Information provided by:
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
First received: October 24, 2002
Last updated: December 15, 2005
Last verified: December 2005
The purpose of this study is to determine whether the combination of Zenapax, CellCept, Cyclosporine and Corticosteroids are effective in patients receiving heart transplants.

Condition Intervention Phase
Phase 4

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:


Ages Eligible for Study:   13 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Undergoing heart transplant
  • Males or females who are 13 years or older
  • Women of childbearing potential must have a negative pregnancy test
  • Must be able to swallow tablets
  • Must be able to understand and comply with the study

Exclusion Criteria:

  • Previous transplants
  • Patients receiving multiple organs
  • HIV or Hepatitis
  • Patients with certain blood disorders
  • Patients who are taking certain experimental medicines
  • Women who are lactating or pregnant or who are unwilling to use two reliable forms of contraception
  • Severe diarrhea or other stomach problems
  • Cancer within the past 5 years (except for skin cancer that is treated)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00048165

  Show 36 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00048165     History of Changes
Other Study ID Numbers: NR15880 
Study First Received: October 24, 2002
Last Updated: December 15, 2005
Health Authority: United States: Food and Drug Administration

ClinicalTrials.gov processed this record on February 04, 2016